Previous 10 | Next 10 |
2024-04-01 15:15:02 ET RBC Capital analyst issues BUY recommendation for OPRX on April 1, 2024 02:00PM ET. The previous analyst recommendation was Buy. OPRX was trading at $11.525 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current an...
2024-03-28 14:10:26 ET More on OptimizeRx OptimizeRx Corporation (OPRX) Q4 2023 Earnings Call Transcript OptimizeRx: Exponential Growth Drives The Valuation Cheaper Read the full article on Seeking Alpha For further details see: OptimizeRx Q4 revenue $28.4M
2024-03-28 11:20:24 ET OptimizeRx Corporation (OPRX) Q4 2023 Earnings Conference Call March 28, 2024, 08:30 AM ET Company Participants William Febbo - CEO Edward Stelmakh - Chief Financial and Operating Officer Steve Silvestro - Chief Commercial Office Conf...
Swire Pacific Ltd. ADR (Class A) (SWRAY) is expected to report for Q4 2023 Troika Media Group Inc. (TRKAQ) is expected to report for quarter end 2023-12-31 American Environmental Partners Inc. (AEPT) is expected to report for quarter end 2023-12-31 Veolia Environnement S.A. ADR (VEOEY...
2024-03-27 13:20:24 ET More on OptimizeRx OptimizeRx: Exponential Growth Drives The Valuation Cheaper OptimizeRx provides update on the timing of earnings call OptimizeRx says preliminary 2023 revenue expected to exceed previously announced guidance range of $68-$70M...
2024-03-27 09:11:56 ET Major earnings expected before the bell on Thursday include: CV Sciences ( OTCQB:CVSI ) Hut 8 ( HUT ) MSC Industrial Direct ( MSM ) Walgreens Boots Alliance ( WBA ) 22nd Century Group ( XXII ) Read the full article on ...
WALTHAM, Mass., March 25, 2024 (GLOBE NEWSWIRE) -- OptimizeRx Corp . (the “Company”) (Nasdaq: OPRX), the leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professional (HCPs) and patients, will hold a confer...
2024-03-22 19:46:57 ET Summary OptimizeRx is experiencing exponential topline growth, but the market has not reacted to their stellar guidance, presenting a potential opportunity for a valuation re-rate in 2024. OptimizeRx provides a software suite called Dynamic Audience Activati...
Weir Group plc ADR (WEGRY) is expected to report for Q4 2023 So-Young International Inc. (SY) is expected to report for quarter end 2023-12-31 Atara Biotherapeutics Inc. (ATRA) is expected to report $-0.61 for Q4 2023 Adyen NV ADR (ADYEY) is expected to report for Q4 2023 Five Bel...
2024-03-14 16:44:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
News, Short Squeeze, Breakout and More Instantly...
OptimizeRx Corporation Company Name:
OPRX Stock Symbol:
NASDAQ Market:
OptimizeRx Corporation Website:
WALTHAM, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- OptimizeRx Corp . (the “Company”) (Nasdaq: OPRX), the leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professional (HCPs) and patients, today announced ...
1Q24 revenue expected to grow over 40% year-over-year and come in between $18.5 - $19.2 million First quarter revenue and adjusted EBITDA to come...
1Q24 revenue expected to grow over 40% year-over-year and come in between $18.5 - $19.2 million First quarter revenue and adjusted EBITDA to come in ahead of consensus DAAP adoption and cross selling activities are tracking ahead of internal expectations WALTHAM, Mass...